About Us
The idea for Vibe Bio began in 2021 when our founder, Alok, had his first child.
When Vibe Bio founder Alok Tayi and his wife had their first child, she was born very sick and spent a long time suffering in the hospital.
The biology behind her conditions is well understood, but there were no therapeutic options available to her. They felt frustrated and alone.
Through that experience, Alok connected with other families with sick children in the NICU and realized that the problem with drug development is not that we can’t find cures; it’s that we don’t have the funding to do it. That’s what motivated him to create Vibe Bio, which will give biotechs unprecedented access to unlock financing and a community to support them along the way.
In this circumstance, it became a passion for our team to understand why medicines aren’t being developed when patients are suffering. Through this process, our insight became that the challenge isn’t finding a cure, but funding it. So, we set out to build Vibe Bio.
Our core is a community of scientists, patients, VCs, and biopharma thought leaders that are committed to identifying, funding, and developing promising treatments that patients deserve. We’re leveraging the power of AI to enable biotechs to significantly increase their drug programs’ probability of success.
What we believe
AI is the future of drug research & development
At Vibe Bio, we see AI not just as a tool, but as a revolutionary force reshaping the future of drug development. By harnessing its immense predictive power, AI accelerates the discovery and development of new treatments, drastically reducing the time and cost traditionally associated with these processes.
It can analyze vast datasets to identify potential drug candidates, predict their efficacy, and foresee side effects, making the R&D process more efficient and effective. This means faster, more informed funding decisions, propelling game-changing therapies across the finish line. For us, AI drug diligence isn’t just the future, it’s the now – the key to unlocking life-saving innovations and bringing hope to patients sooner than ever before.
Unlocking capital should not be a barrier to drug development
We understand that the most life-changing medical breakthroughs lie just beyond the next crucial funding milestone for many promising biotech companies. Access to capital isn’t simply a hurdle; it’s the fuel that propels these groundbreaking discoveries from the petri dish to the real world.
We believe that investing in biotechs at these pivotal inflection points isn’t just a sound financial decision; it’s a chance to directly contribute to the advancement of medical science and potentially improve the lives of millions. For us, it’s not just about investing in promising science, it’s about investing in the potential to transform healthcare and impact the world in the most profound way possible.
All of us should have the power to pursue a cure
Every scientist, patient, family member, etc. with a life-altering disease — no matter how rare it is — should feel a part of a community with the power to pursue their cure. But too many promising treatments to overlooked diseases are abandoned because the treatments they need are considered too costly and too risky.
FAQ
About Vibe Bio
Vibe Bio analyzes and invests in promising drug programs. Our drug analytic software, VibeOne, uses artificial intelligence (AI) to help pharmaceutical companies diligence drug R&D. Vibe Bio is advancing projects that currently are not getting the funding and attention they deserve.
We believe in the potential applications of decentralized and distributed science. One important component of DeSci is data accessibility. The VibeOne platform can provide data-driven insight solutions for our partners and we would love to partner with you.
We consider rare disease research and drug development incredibly important for both patients and researchers. One in ten Americans have a rare disease. By advancing the research needed for drug development, patients will benefit by having more life-changing therapies available to them.
Our mission is focused on finding every cure for every community. Vibe Bio helps biotechs by funding & guiding high-potential drug programs at critical inflection points. Our core is a community of scientists, patients, VCs, and biopharma thought leaders that are dedicated to helping you find the promising treatments that patients deserve.
You can reach out to us with your proposals for co-marketing activities, reciprocal thought-leadership, and investment opportunities. We are always eager to connect with patients, families, advocates, scientists, VCs, biopharma companies, and others who are as passionate as we are about financing treatments for overlooked diseases.
About The Fund
The software analyzes large datasets of scientific data, including pre-clinical and clinical data, to identify patterns and trends that may not be visible to the human eye. This information can then be used to assess the risks and rewards of different drug projects, and to make more informed decisions about where to allocate resources.
Our due diligence team considers an array of variables in order to make a decision based on scientific merit and clinical opportunity. Our mission to find every cure for every community empowers us to invest in a variety of therapeutic areas.
Yes, you can! To learn more about investing opportunities, you can get in touch with us here.
First, create an account and prepare to submit your work. Biotechs reach out to Vibe Bio with their most promising drug projects, highlighting upcoming milestones and their path to the next crucial stage. Through the application process, you’ll be asked to upload non-confidential data and a deck that will help us understand your drug’s R&D.
Once you submit all of your information, our expert diligence team and analytic software, VibeOne, closely examine the scientific and financial data, assessing the drugs feasibility. If we decide to move forward, both parties will sign NDAs and proceed with more in depth review of the company’s data room.
About AI Analytics
VibeOne uses a variety of AI techniques, including machine learning, deep learning, and natural language processing. The software is able to learn from the data it analyzes and improve its accuracy over time.
The software analyzes large datasets of scientific data, including pre-clinical and clinical data, to identify patterns and trends that may not be visible to the human eye. This information can then be used to assess the risks and rewards of different drug projects, and to make more informed decisions about where to allocate resources.
When submitting program information to Vibe Bio for possible fund consideration, all information is stored privately, securely, and inaccessible to anyone but appropriately-credentialed Vibe employees.
At no point will your proprietary information ever be exposed or used to train publicly-available models. Vibe Bio’s own work product may be anonymized and aggregated for future benchmarking and reporting.
Vibe Bio’s AI software is not available for external use at this time. If you’re interested in leveraging our software and data platform or collaborating with us, please reach out.